Shots: The companies will collaborate to develop, manufacture, and distribute AT-527 to combat COVID-19. If approved, Atea will be responsible for distributing the treatment option in the US, with the option to request Genentech’s support, and Roche will be responsible for distribution outside the US The therapy is currently being evaluated in P-II study for […]Read More
Shots: The companies collaborate for fast-track development of DNP-019 against COVID-19 The collaboration will expand Samsung’s CDO capabilities to provide a full scope of its development services from cell line development, process development, to non-clinical and clinical material manufacturing Samsung has introduced its proprietary cell-line technology, S-CHOice, demonstrating improved titers up to two-fold and maintaining […]Read More
Shots: Genesis to receive an up front and is eligible to receive pre/ clinical and regulatory milestones along with royalties on sales of approved drugs emerges from the collaboration The collaboration leverages Genesis’ graph machine learning and drug discovery expertise to identify drug candidates for therapeutic targets across multiple disease areas Genesis has developed Dynamic […]Read More
Shots: Takeda has entered into a five-year agreement with Accenture and Amazon Web Services (AWS) to support the company in moving 80% of its applications to the cloud and modernizing its research tools The transition of Takeda’s applications to the cloud will enable the company to remove non-differentiating technology and create a scalable architecture. The […]Read More
Shots: Arrowhead to receive ~$300M up front, ~$740M as development, regulatory and commercial milestones and is eligible to receive royalties of 20-25% on net sales If approved, the companies will co-develop ARO-AAT and co-commercialize it in the US, under 50/50 profit sharing structure. Additionally, Takeda will lead the global commercialization strategy and get an exclusive […]Read More
Shots: Scenic to receive ~$375M that includes up front, milestones along with royalties on sales of therapies emerges from the collaboration and will receive additional target fees for the therapies selected by Genentech The collaboration allows the Genentech to select multiple targets for further development with an option to extend the collaboration. Scenic will leverage […]Read More
Shots: The companies enter in a global Ab manufacturing collaboration to expedite the global supply of Lilly’s COVID-19 therapies With the agreement, the two companies will have the ability to ramp up the production and serve more patients globally, once Lilly’s Ab therapies prove successful in clinical testing and receive regulatory approval Lilly is currently […]Read More
Shots: The companies will evaluate SpringWorks’ Nirogacestat (GSI) in combination with Janssen’s Teclistamab (Ab targeting BCMA and CD3) in patients with r/r MM. The companies anticipate commencing the study by early 2021 Janssen to sponsor and conduct a P-I study assessing the safety, tolerability, and preliminary efficacy of the combination, and will assume all costs […]Read More
Shots: Redx to receive $10M as up front followed by another $10M in year two and will receive up to $400M as milestones along with royalties on sales of the therapies. The first milestone is payable following IND submission Following a successful IND submission, Jazz will be responsible for further development, manufacturing, regulatory activities, and […]Read More
Shots: Recursion to receive $30M as up front, $50M as equity investment, ~$100M/ program as development and commercial milestones along with royalties on sales. The companies will work on more than ten programs Bayer will get an exclusive option to license novel therapies derived from the research activities The collaboration will deploy Recursion’s AI-guided drug […]Read More
Copyright ©2020 PharmaShots | Powered by Octavus Consulting
